Fisher & Paykel Healthcare Corporation Limited advises that Lisa McIntyre, PhD, has been appointed as a non-executive director of the company with effect from 1 October 2021.
“We are pleased to announce Lisa’s appointment and look forward to the insight she will bring to the Board,” said Scott St John, Board Chair.
“Lisa has extensive knowledge in health and technology – with experience in strategy, finance, technology transformation and data analytics. She has a deep understanding of international markets and a reputation for insight, integrity and transparency.”
Dr McIntyre is an experienced company director with a broad portfolio that spans the health care, insurance, technology and e-learning sectors. She is currently a non-executive director of Insurance and Care NSW (a government public financial corporation), HCF Group (a private health insurance company in Australia), The University of Sydney, Studiosity and Nanosonics, and chair of LEK Consulting’s ANZ Advisory Board.
Prior to her director roles, Dr McIntyre spent 20 years as a senior strategy partner with LEK Consulting. She helped develop the company’s US biotechnology advisory practice from three clients in the emerging sector to become the largest biotechnology practice in the US, providing strategic, commercial and operational advice to local and multinational companies in North America, Asia and Australia.
The Fisher & Paykel Healthcare Board has determined that Dr McIntyre will be an independent director of the Board. She will also serve as a member of the Quality, Safety and Regulatory Committee, effective 1 October 2021.
A resolution to elect Dr McIntyre will be put to shareholders at the company’s next annual shareholders’ meeting in August 2022. Dr McIntyre replaces Tony Carter, who retired from the Board in August 2020.
About Fisher & Paykel Healthcare
Fisher & Paykel Fisher Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
GM Corporate Communications
+64 (0) 21 713 911
Investor Relations Manager
+64 (0) 27 807 8073
Lisa McIntyre appointed to Fisher & Paykel Healthcare Board
Evidence and guidance for delivering Optiflow NHF, proven respiratory support for your patients.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks and full face NIV masks, with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Delivering warm, humidified carbon dioxide in laparoscopic and open surgery
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment